Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib + Pomalidomide in RRMM
NCT03143985Phase 1Completed
- Start
- Jul 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vactosertib in multiple myeloma (MM). Primary endpoints: Maximum Tolerated Dose and Safety and Tolerability Profile. Started Jul 2017; status: completed.
02
Drugs
vactosertib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03143985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143985.